Purpose: To estimate the accuracy of predicting response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast cancer using MR spectroscopy (MRS) measurements made very early in treatment. was assessed for its ability to predict pathologic complete response (pCR) and radiologic response using the area under the receiver operating characteristic curve (AUC) and logistic regression models. Results: Of the 119 subjects enrolled, only 29 cases (24%) with eight pCRs provided usable data for the primary analysis. Technical challenges in acquiring quantitative MRS data in a multi-site trial setting limited the capture of usable data. In this limited data set, the decrease in tCho from TP1 to TP2 had poor ability to predict either pCR (AUC 5 0.53, 95% confidence interval [CI]: 0.27-0.79) or radiologic response (AUC 5 0.51, 95% CI: 0.27-0.75). Conclusion: The technical difficulty of acquiring quantitative MRS data in a multi-site clinical trial setting led to a low yield of analyzable data, which was insufficient to accurately measure the ability of early MRS measurements to predict response to NACT. Level of Evidence: 1 Technical Efficacy: Stage 2
S
ystemic chemotherapy in combination with surgery is currently the standard treatment for women with locally advanced breast cancer (stages IIb and III). Neoadjuvant chemotherapy (NACT) (systemic therapy before definitive surgery) has the advantage of increasing the rate of breast conservation surgery. 1, 2 NACT also provides an opportunity to monitor an individual patient's response and tailor her therapeutic regimen. Such adaptive therapy requires a minimally-invasive means to distinguish responders from nonresponders early in the course of treatment. Several studies have shown that contrast-enhanced MRI can distinguish responders from nonresponders after the first cycle of NACT. [3] [4] [5] Previous work has suggested that changes in the total choline (tCho) signal, as measured by MR spectroscopy (MRS), may provide an earlier indicator of treatment response than size changes. Breast cancers commonly exhibit an elevated level of tCho due to changes in phospholipid metabolism, 6 which have been attributed to frequent mutations in choline kinase and other enzymes. 7 An early clinical study by Kvistad et al 8 observed that the in vivo tCho signal disappeared in response to successful chemotherapy. Several subsequent studies found that a decrease in tCho signal during chemotherapy was associated with favorable pathologic [9] [10] [11] [12] and radiologic responses. [13] [14] [15] While the above studies looked at tCho changes measured tCho 1 or more weeks after starting chemotherapy, in vitro studies have shown that taxane treatment leads to cell death on the 24-48 h timescale, 16 (I-SPY TRIAL) , which studied imaging-and tissuebased biomarkers for predicting response and survival. The purpose of this study was to estimate the accuracy of predicting response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast cancer using MRS measurements made very early in treatment.
Materials and Methods

Participant Eligibility and Enrollment
Female patients enrolling in CALGB 150007 who had tumors that measured at least 3 cm in diameter by clinical examination or imaging, and who were receiving NACT with a weekly paclitaxelbased regimen for 12 weeks, in combination with optional trastuzumab for HER 1 patients, followed by four cycles of an anthracycline-cyclophosphamide regimen, were eligible for this prospective study. Pregnant patients and those with ferromagnetic prostheses, intracranial aneurysm clips and other absolute contraindications to MRI were excluded from the study. Following amendments to both the CALGB 150007 and ACRIN 6657 protocols, both studies were re-opened to enrollment from September 2007 to April 2010. Patients signed a single consent form for both studies. The Health Insurance Portability and Accountability Act (HIPAA)-compliant protocol and informed consent process were approved by the American College of Radiology Institutional Review Board and local-site institutional review boards. Patients were screened for eligibility, consented, enrolled through CALGB 150007, and then registered to ACRIN 6657-ext.
MRS Quality Control
As MR spectroscopy of the breast is not routinely used in clinical practice, a training and quality control program was used to help control MRS data quality. 18 Before enrolling patients, each site was required to qualify by submitting MRS measurements with acceptable accuracy and spectral quality from a trial-specific spectroscopy phantom (detailed in the Appendix). Two sequence variations were allowed to account for variations between vendors: a measurement with fixed echo time of 125 ms, 64 or more averages, and optional fat suppression; or a TE-averaged 19 acquisition using an array of echo times from 50-200 ms in 64 or more increments. The trial team provided consultation and training materials to help standardize MRS data acquisition, file transfer, and in vivo voxel placement. Throughout study accrual the trial team monitored data quality from both in vivo and scheduled phantom scans, and provided sites with feedback and consulting as needed.
Imaging and Spectroscopy Data Acquisition Procedures
MR imaging and spectroscopic examinations were performed within 4 weeks before the start of the first chemotherapy regimen (time point 1, TP1), 1-4 days after the first cycle of treatment (TP2), between the first and second chemotherapy regimens (TP3), and after the second regimen and before surgery (TP4). The 1-4 day timing of the TP2 scan was further divided into 1-day (20-28 h) and 2-4 day (48-96 h) windows, based on scheduling preference.
Examinations TP2-4 were performed on the same MR system or similar system (same vendor, breast coil, and field strength). The MRI data from TP3 and the MRS data from TP3 and TP4 were not considered for the analyses in this manuscript. The MRI and MRS acquisition protocols were the same for all time points. MR examinations were performed with either 1.5 Tesla (T) or 3T MR scanners (determined by availability) using a dedicated breast radiofrequency coil and prone positioning. The acquisition protocol included a localizer, a T 2 -weighted sequence, a contrastenhanced image series, and finally MRS. The contrast-enhanced series consisted of a high-spatial-resolution (in-plane spatial resolution 1 mm) three-dimensional (3D) fat-suppressed T 1 -weighted imaging volume acquired either bilaterally (with axial orientation) or unilaterally (in sagittal orientation) using a gradient-echo sequence with a repetition time of 24 ms or less, minimum echo time with water and fat in phase, a flip angle of 45 8 or less, a field of view 16-18 cm (sagittal) or 32-40 cm (axial), a minimum matrix of 256 3 192 (sagittal) or 512 3 384 (axial), and 64 or more sections with a thickness of 2.5 mm or less. Imaging time for the T 1 -weighted volume was required to be a maximum of 3 min. The first volume in the series was acquired before injection of a gadolinium-based contrast agent at a dose of 0.1 mmol/kg over 15 s, followed by a 10-mL saline flush over 15 s. The second volume acquisition was started simultaneously with the contrast agent injection, and additional volumes were acquired sequentially for a minimum of 8 min postinjection.
MR spectroscopy was performed after the completion of the contrast-enhanced series. For each subject's pretreatment scan (TP1), a 3D cubic voxel was prescribed to cover the enhancing lesion as much as possible while excluding adipose tissue, normalappearing fibroglandular tissue, necrotic regions, and artifacts due to biopsy tissue markers ("clips"), using the postcontrast images for guidance. The voxel size was variable with a minimum of 10 mm per side. For subsequent scans (TP2-4), operators were instructed to adjust the voxel size and position as needed to best imitate the voxel placement of the TP1 scan (e.g., if the lesion shrank the voxel should as well). Operators also recorded their confidence (on a 1-5 scale) that the voxel was well-placed based on the above criteria. After static field shim adjustments a water reference scan and a "metabolite" scan were acquired using a PRESS 20 localization sequence. The water reference scan was acquired with 5 echo times (TE 5 50, 75, 100, 125, 150 ms), repetition time 6 s, 1 or 2 averages, and resonance frequency set on water at 4.7 ppm. The metabolite scan was acquired with water suppression enabled, repetition time 3 s, and the resonance frequency set at 3.2 ppm.
MR Imaging Analysis
Image data were de-identified and centrally archived at the Ameri- 
MR Spectroscopy Analysis
De-identified MRS data were transferred from the American College of Radiology Imaging Core Laboratory to University of Minnesota for processing. MRS analysis was based on the methods previously described. 22 Preprocessing for all spectra included frequency and phase adjustments, noise normalization, Lorentzian line broadening, and zero-filling to produce comparable spectral discretization for both field strengths. The water reference spectra were processed by fitting water and 1.3 ppm lipid resonances with a Voigt lineshape. The peak amplitudes for each echo time were fit with a monoexponential model to estimate the T 2 relaxation rate and T 2 -corrected amplitude for both water and lipid, as well as the lipid fraction (defined as lipid/(water1lipid)). The individual traces from the metabolite scans were individually phase and frequencycorrected 23 before averaging.
The residual water and lipids were fit with Voigt lineshapes and removed to reduce baseline distortions before fitting a total choline (tCho) resonance at 3.2 ppm. A tCho peak was considered detectable if four criteria were met: peak frequency-domain signalto-noise 2, ratio of tCho to water linewidth 0.33 (to avoid fitting noise), Cramer-Rao minimum variance bound 200%, and tCho center frequency between 3.1 and 3.3 ppm. After fitting the datasets were manually reviewed and those with poor quality (e.g., poor shim, artifacts, baseline, etc.) were removed from the analysis set. The tCho and water amplitudes were then converted to a concentration in units of mmol tCho per kilogram water as described previously, 22 with the exception that water T 2 was measured and corrected in each dataset rather than using an assumed water T 2 . The T 2 for tCho was taken from the literature using 263 ms at 1.5T [24] [25] [26] and 204 ms at 3T. 27 If a tCho peak was not detected at TP1, the concentration was considered unmeasurable. A representative case showing results of imaging and spectroscopic analysis is shown in Figure 1 .
Histopathologic Analysis
Histopathologic analysis of surgical specimens was performed locally by each institution's pathologist. pCR was reported when no residual invasive disease was present in the breast and axillary lymph nodes (ypT0/is, ypN0). Hormone receptor (HR) positivity (ER-positive and/or PR-positive) and HER2 receptor expression were determined from pretreatment core biopsy by immunohistochemistry and Allred score. For subtype analysis, patient groups were defined as those with HR1/HER2-, HER21, and HR-/HER2-(triple negative, TN) tumors.
Statistical Analysis
The primary analysis was to determine if a change in tCho concentration from pretreatment to the early treatment time point, defined as nonmass], and morphologic sub-classification) were identified and independently evaluated using logistic regression models.
For the primary and secondary analyses, P-values less than 0.05 were considered significant. Exploratory analyses also used an alpha of 0.05 to identify potential effects. All statistical data analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC).
Results
Inclusion and Data Quality
One hundred nineteen subjects were enrolled in the extension trial. Seven subjects withdrew before completing the study, three were ineligible due to development of metastases, two received a noncompliant treatment regimen, and five were imaged at incorrect timepoints. MR spectroscopy data at either the first or second time-points was not acquired (n 5 20) or lost (n 5 15) in 35 of the remaining 102 cases, leaving 67 cases with MRS data available at both TP1 and TP2. Of these, 16 had poor quality MRS at either TP1 or TP2, and 18 had no measurable tCho at either TP1 (n 5 15) or TP2 (n 5 3), leaving 33 cases with analyzable MRS. In addressing the primary outcome of pathologic response, 4 subjects did not have final pathology data available, leaving 29 cases in the analysis set with a pCR prevalence of 28% (8/29) . In addressing the secondary outcome of radiologic response, 5 did not have acceptable volume data at either TP1 or TP4, leaving 28 cases in the analysis set. Table 1 presents the participant characteristics of the study population and these two analysis sets. No significant differences were observed between any characteristics of the excluded versus the included cases for each set (P > 0.05). 
Pathologic Response
Radiologic Response
The median change in FTV from TP1 to TP4 (%DFTV 1!4 ) was -94.75%; subjects with a greater decrease than this median value were considered radiologic responders. Figure 3 (Spearman q 5 -0.07; P 5 0.72).
Repeating the above analyses using the relative change in tCho (%D[tCho] 1!2 ) showed that it was a poor predictor of %DFTV 1!4 (AUC 5 0.52, 95% CI: 0.29-0.74) and showed no significance using either Fisher's exact test (P 5 0.38) at the optimal cutoff (20.6%), univariate logistic regression (P 5 0.42, OR 5 0.52, 95% CI: 0.11-2.57), or Spearman's correlation (Spearman q 5 -0.04; P 5 0.84).
Unmeasurable Pretreatment tCho
The inability to measure the tCho level at the pretreatment time-point reduced the amount of analyzable data for all outcomes tested. Of the 14 potential explanatory factors listed above, only 4 were significant when tested with univariate logistic regression: lipid fraction (P 5 <.001), voxel size (P 5 0.04), water line width (P 5 0.002), and field strength (P 5 0.006). No tCho was detected in voxels with lipid fraction > 33%; for voxels with lipid fraction 33% the detection rate was 66%. The tCho detection rate was lower in voxels larger than the median size (50% for voxels 7.7 mL; 71% < 7.7 mL), and in voxels with broader water line widths (33% for water line width > 0.25 ppm; 73% for water line width 0.25 ppm) The detection rate at 1.5T (53%) was lower than that at 3T (93%).
Exploratory Analyses: Early Changes in Water T 2 and FTV Larger analysis sets were available for assessing two exploratory predictors of pCR, DT 2 w 1!2 and %DFTV 1!2 . Good quality T 2 w measurements were available for both TP1 and TP2 in 60 cases (59%, 60/102), and 56 of these also had a known pCR status. The change in water T 2 (DT 2 w 1!2 ) showed a significant association (P 5 0.004) with pCR when dichotomized at the optimal cutpoint (cutoff 5 -6.9 ms), with AUC 5 59.7%. FTV measurements were available for both TP1 and TP2 in 68 cases (67%. 68/102), and 64 of these had a known pCR status. The early decrease in FTV (%DFTV 1!2 ) showed a significant association (P 5 0.007) with pCR when dichotomized at the optimal cutpoint (cutoff 5 -24.7%), with AUC 5 64.3%.
Discussion
The ACRIN 6657 extension trial was designed to estimate the accuracy of predicting pathologic and radiologic response to NACT using a change in tCho concentration measured by MR spectroscopy within the first 1-4 days after beginning chemotherapy. Due primarily to the technical challenges of Surgical pathology P-value* 1.000 1.000 acquiring quantitative breast MRS in a multi-site clinical trial setting, only 28% (29/102) of the eligible cases were usable for the primary analysis, leading to substantially reduced statistical power. Thus, this study was not able to measure the accuracy of predicting pathologic response with MRS with sufficient precision to assess its clinical utility. There was some evidence of a relationship between tCho change and radiologic response: while the estimate of the predictive value was not significantly different than 0.5, there was a statistically significant difference in radiologic outcome when dichotomizing tCho change at the optimal cutpoint. This is attributable to those cases where tCho increased the most: the five subjects with the largest increase in tCho were radiologic nonresponders. While a positive finding, this should be interpreted cautiously, as there was no overall correlation between tCho change and radiologic response, and ROC analyses can lead to overoptimistic results with small sample sizes. 30 Previous studies using tCho to predict treatment response in breast cancer have generally found that a decrease in tCho indicates a favorable response to chemotherapy. An important difference between this trial and the majority of previous studies is the timing of the first posttreatment MRS measurement. This trial measured patients 1-4 days after the first treatment, which reflects a more acute response than studies that measured tCho after completion of the first cycle of chemotherapy (2-4 weeks). [9] [10] [11] [12] [13] [14] 31 The only other study that looked at a comparably acute posttreatment timing was Meisamy et al 17 which had a posttreatment (TP2) timing window of approximately 12-36 h and reported 100% accuracy for predicting radiologic response (defined by tumor longest diameter measurements). This trial used a wider TP2 window to ease patient scheduling and allow analysis of time variation within that window (which was not possible with the limited data available). It may be that the acute timing used here is too early to reliably detect metabolic changes, or that the optimal TP2 timing depends on the therapeutic agent. Our trial also found a relationship between tCho change and radiologic response based on FTV, but the predictive value was poor. An alternate analysis of this trial's data using the lesion longest diameter (measured at each site) as outcome also showed no significant findings (data not shown). The primary difference between these two studies was the environment: Meisamy et al was a small (n 5 13), single-site pilot study using a nonstandard 4T MR system and methods, whereas this trial was performed across nine sites with standard clinical 1.5 or 3.0T MR systems, coils, and software from multiple vendors. Along with the lower field strengths, the heterogeneity in systems, sequences, and operators may have contributed to lower performance of this trial.
The low yield of analyzable data was the primary limitation of this study. This led to wide confidence intervals and made relevant subgroup analyses (e.g., grouping by receptor status, timing of TP2, field strength, highest data quality, postbiopsy timing) impractical. Three factors accounted for the majority of this data loss, each of which is attributable to the technical challenge of acquiring quantitative MRS data, despite protocol-specific site qualification and training. First, sites did not submit MRS data for both Second, poor quality MRS data eliminated 24% (16/67) of cases from the analysis sets. The low quality was attributed to multiple factors, including errors in scanner adjustments (transmit power, B0, and frequency), poor voxel placement and/or localization quality, and patient motion. Five cases were eliminated due to a single system that produced inconsistent data, as determined retrospectively from analysis of the phantom quality control data. Third, a tCho resonance was not detected using the specified objective criteria for either TP1 or TP2 in 37% (18/49) of the cases otherwise eligible for analysis. This nondetection rate is comparable to the 40% reported by Bathen et al 31 Large voxel sizes, high lipid fractions, and large water line widths (indicating poor B0 shimming) were associated with nondetection of tCho, suggesting that voxel placement and avoidance of adipose tissues were challenging. The presence of biopsy markers, which were used in all patients, may also have complicated voxel placement and/or impacted the spectral quality. The tCho detection rate was higher at 3T than 1.5T, suggesting that the higher signal-to-noise and spectral resolution improved detectability. The two exploratory metrics, DT 2 w 1!2 and %DFTV 1!2 , were more robustly measurable than D[tCho] 1!2 and thus allowed for substantially larger analysis sets. Decreases in T 2 w and FTV measured at TP2 were both found to have a significant association with pathologic response. These findings indicate that MR-measurable changes in tumor vascularity (reflected in FTV) and microstructure (reflected in T 2 w) occurring within 1-4 days of initiating chemotherapy can assess drug efficacy, and may be useful for adapting chemotherapy regimens.
The findings of this trial suggest several recommendations for future development and assessment of breast MRS. First, real-time placement of the acquisition voxel is challenging and operator-dependent, and likely contributed to data loss and variability between sites. Options to reduce this variability include automated voxel placement, increased training and oversight of operators, and/or spectroscopic imaging methods that allow for retrospective region selection.
14,32-34 Second, the inclusion of variable MR systems in this study required flexibility in the acquisition protocol and contributed to variability between sites, and likely gave lower performance than a study using controlled scanning platforms. This heterogeneous design is widely used Responder (n 5
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[tCho] 1 (mmol/kg) successfully for imaging studies, and at the time of study design the number of encouraging single-site breast MRS studies led expert groups to recommend multi-site, multivendor studies of breast MRS. 35 In retrospect, future studies would benefit by more rigorous standardization of acquisition methods, including limiting the eligible systems to high-field (3T) scanners, which gave better detection performance and are more widely available today. While this trial did implement a quality control program using initial qualification and ongoing monitoring (see the Appendix), future trials would benefit from stronger quality controls, including more timely feedback to enforce data quality and protocol compliance. Third, the results from this study do not provide evidence that acute posttreatment timing is better than later timepoints. While it is preferable to detect nonresponse as early as possible, study designs that acquire MRI/MRS after a full cycle of therapy may provide better performance while simplifying patient scheduling. Finally, while a decrease in tCho could not identify patients who would achieve pCR, the lack of an early decrease in tCho was associated with a lack of change in tumor size. While this study was too small to analyze specific cancer subtypes (e.g., HR1, HER1, TN), it is possible that tCho changes may provide more meaningful information in specific subgroups. Our results could be used to design further studies using more controlled MRS methods to assess response in specific breast cancer subgroups. 
Appendix
MRS Quality Control
As this trial was designed to test breast MRS in a heterogeneous clinical setting, which included different MR scanners, field strengths, breast coils, and software capabilities, several quality control measures were used to maximize data consistency. These measures were described prospectively in the trial protocol and a conference abstract (18) . A pair of trial-specific test phantoms were produced in a single batch and distributed to all sites. The normal phantom consisted of a 2-liter leak-proof bottle containing vegetable oil and a 40 mm outer diameter plastic sphere mounted on a post 2 inches above the bottom. The sphere contained 1 mM phosphocholine, 0.2 mM Gd-DTPA, 10 mM deuterated TSP as a frequency reference, and 0.1% sodium azide. The control phantom was identical to the normal phantom except it contained no phosphocholine. Before enrolling human subjects, each site was required to submit an acceptable Entry QC scan of the normal and control phantoms for each system that was to be used in the trial. A system was defined as the combination of MR scanner, breast coil and software. For example, when a scanner received a software update it was treated as a new system, and a new Entry QC submission was required before acquiring additional in vivo data. The Entry QC scan consisted of six scans: a water reference scan, a metabolite scan, and a metabolite scan without water suppression acquired from a 20 3 20 3 20 mm voxel placed in the sphere of both the normal and control phantoms. To be considered acceptable the data were required to show a water-fat ratio > 2 (indicating acceptable localization performance), water linewidth < 0.25 ppm (indicating system shimming performance), a detectable tCho resonance in the normal phantom, and no detectable tCho resonance in the control phantom. Additionally, the system sidebands were measured using the metabolite scan without water suppression; if the water sidebands were > 5 0.002% in the 1.2-2.7 ppm range around the water peak, then either TE averaging or lipid suppression would be required to avoid the possibility of a sideband from a large lipid peak interfering with the tCho measurement (19) . The Entry QC testing was used iteratively to determine which acquisition variations ( 6 fat suppression, single TE versus TE averaging) gave the best performance on a per-system basis. Details for each system used in the trial are provided in Table A1 , and the individual participant characteristics for each site are given in Table A2 . After qualifying for the study, regular biweekly quality control scans were acquired for each system to measure within-system phantom reproducibility, which reflects the phantom measurement precision for a longitudinal study. The mean and coefficient of variation (standard deviation / mean) of the biweekly [tCho] measurements for each system are also provided in Table A1 . In addition to phantom measurements, in vivo measurements were assessed with subjective quality scoring. All spectra for the study were assessed during the final analysis in random order by an experienced spectroscopist blinded to imaging and outcome information. Spectra were assigned scores of good, fair, or poor based on the presence of artifacts, the quality of the data (linewidth, lineshape, and baseline), and the quality of the spectral fitting. Specific findings, such as poor baseline, poor fit, etc., were recorded. All spectra with "poor" scores were eliminated from analysis sets, while both "good" and "fair" datasets were included. Of the 165 spectral datasets submitted for TP1 and TP2, 47 (28%) were assigned good quality, 85 (52%) fair, and 33 (20%) poor quality. The poor quality scores were attributed to an unstable software upgrade on a single system (12), a RF transmit calibration error on a single system (9) , inconsistent adjustments between water and metabolite scans (5), incomplete acquisitions (3), poor shim and baseline distortions (3), and motion (1). *System F.4 was retrospectively found to perform inconsistently, and its data were excluded from analysis sets
